Clinical Trials Management, LLC | Southshore, Metairie, LA
Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the efficacy and safety of Povorcitinib (INCB054707) in participants with moderate to severe Hidradenitis Suppurativa (HS) over a 12-week placebo-controlled period, followed by a 42-week extension period.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
600 participants in 3 patient groups, including a placebo group
Loading...
Central trial contact
Incyte Corporation Call Center (ex-US); Incyte Corporation Call Center (US)
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal